Ispecimen Inc. · NASDAQ:ISPC
Ispecimen — Investor Presentation (February 2022)
28 slides from Ispecimen's investor presentation, Feb 17, 2022
Slide 1: February 2022 Investor Presentation: Transforming Biospecimen Procurement
CONNECT. INNOVATE. February 2022 Investor Presentation ( through Q4 2021) TRANSFORMING BIOSPECIMEN PROCUREMENT An online marketplace for human biospecimens
Slide 2: Forward-Looking Statements
This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . Such forward - looking statements are characterized by future or conditional verbs such as
Slide 3: Management Team
Christopher Ianelli, MD PhD | Chief Executive Officer, President, and Director Dr . Ianelli has been serving as our Chief Executive Officer, President, and Director since founding iSpecimen in July 2009 . Dr . Ianelli served as Chief Executive Officer of Abkine Pharmaceuticals, Inc . Dr . Ianelli se
Slide 4: Investor Highlights
Investor Highlights 4 ~200 Healthcare Provider / Supplier Organizations ~400 Customer Organizations 1. Early - stage opportunity with a first mover advantage 2. $3B - $4B global biospecimen market growing at 10 - 15% per year 1 3. Unique two - sided marketplace disrupting the biospecimen procurement
Slide 5: Our Vision
Accelerate scientific discovery in an online marketplace that empowers researchers to instantly search for and gain access to patients, biospecimens, and data across a global network of healthcare providers Our Vision 5
Slide 6: Human Biospecimens are Essential for Life Science R&D
Human Biospecimens are Essential for Life Science R&D Basic Research Biomarker Identification & Validation Drug Discovery & Development Diagnostics Discovery & Validation Biofluids Solid Tissue Stem & Immune Cells Plasma, Serum, Urine, Saliva Industry Academia Government 6 Lung, Breast, Colon, Brain
Slide 7: Large and Inefficient Biospecimen Market
10 - 15% Annual Growth Fueled by precision and regenerative medicine research 2 Disconnected Market Participants in Need of a Marketplace Solution With an Inefficient Supply Chain Manual processes plus fragmentation make it ripe for an online marketplace solution Large and Inefficient Biospecimen Ma
Slide 8: Market Inefficiencies
Market Inefficiencies PROVIDER RESEARCHER Scientist / Informaticist Procurem ent Legal & Compliance IT / Informaticist Scientist & Informaticist Legal & Compliance IT / Informaticist Researcher & Procurement Legal & Compliance Principal Investigator & Specimen Operations PATIENTS PROVIDERS RESEARCHE
Slide 9: Inefficiencies Lead to Losses
Inefficiencies Lead to Losses Providers miss revenue and research opportunities > 3 Billion clinical specimens are discarded annually worldwide 5 > 1 Billion Patient encounters yearly in the U.S. where a specimen could be provided for research 4 > 800 Million banked specimens are in biorepository in
Slide 10: The iSpecimen Marketplace Solution
The iSpecimen Marketplace Solution 10 PROVIDER Procurement Principal Investigator / Operations IT / Informaticist PATIENTS Legal & Compliance IT / Informaticist Researcher & Procurement Legal & Compliance Principal Investigator & Specimen Operations Scientist & Informaticist Blood / Pheresi s Center
Slide 11: Full-Service Procurement
Full - Service Procurement We Not Only Connect Suppliers and Customers, but We Also Manage the Entire Procurement Process Click to See the Overview Video SPECIMEN SEARCH & SELECTION SPECIMEN LOGISTICS SPECIMEN MANAGEMENT DATA MANAGEMENT STUDY/ORDER MANAGEMENT SUPPLIER SITE TRAINING COLLECTION KIT BU
Slide 12: Suppliers and Researchers Benefit
Suppliers and Researchers Benefit Advance Discovery Suppor t research mission and advance diagnostic, therapeutic, and vaccine research Increase Revenue Instantly connect to a global network of researchers Ensure Compliance On a platform that protects the privacy and security of patient information
Slide 13: Growing Supplier Adoption
13 34 66 102 147 181 200 2015 2016 2017 2018 2019 2020 2021 Growing Supplier Adoption 1000+ Hospitals Also includes three Healthcare Information Exchanges 58% CAGR Number of Suppliers (2015 - 2021) WORLDWIDE COVERAGE United States United Kingdom Germany France Ukraine Georgia Bulgaria Russian Federa
Slide 14: Growing Researcher Adoption
$700 $1,448 $3,067 $4,395 $4,298 $8,184 $11,135 2015 2016 2017 2018 2019 2020 2021 Cumulative Customer Organizations with Purchases 2015 – 2021 61% CAGR Customers (2015 – 2021) Revenue ($000) - Unaudited 2015 - 18, 21 2015 – 2021 59% CAGR Revenue (2015 – 2021) Growing Researcher Adoption 70% of the
Slide 15: Growing Marketplace Adoption
80 118 668 1,587 2,681 3,871 5,218 2015 2016 2017 2018 2019 2020 2021 Cumulative Researcher and Supplier Marketplace Users 2015 – 2021 101% CAGR Registered Users (2015 – 2021) Growing Marketplace Adoption ~4,400 Unique searches performed by researchers in the iSpecimen Marketplace in 2021 ~65% % of
Slide 16: Growing Data Asset
“Utilization of sample data for research and for monetization is the next key value driver for the biobanks.” - Frost & Sullivan, Global Biobanking Market Landscape Growing Data Asset Banked Specimen Records Patient Records Medical Condition Records Clinical Specimen Records Laboratory Test Records
Slide 17: Statements of Operations
Statements of Operations 17 2021 2020 (Unaudited) Revenue $ 11,135,303 $ 8,184,106 Operating expenses Cost of revenue 5,249,013 3,585,477 Technology 1,837,882 1,465,348 Sales and marketing 2,422,743 1,783,563 Supply development 573,913 497,182 Fulfillment 1,363,522 859,643 General and administrative
Slide 18: Balance Sheet
Balance Sheet As of December As of December 34, 2021 34, 2020 Assets Cash S$ 27,738,979 s 695,909 Accounts receivable - unbilled 1,739,020 652,761 Accounts receivable, net 3,002,442 1,526,392 Prepaid expenses and other current assets 327,035 417,929 Tax credit receivable, current portion 140,873 179
Slide 19: Fully Diluted Shares of Common Stock Outstanding
19 Fully Diluted Shares of Common Stock Outstanding Diluted Common Shares Shares outstanding at December 31, 2021 8,733,479 Shares issuable upon vesting of RSUs 285,542 Shares issuable upon exercise of stock options 257,717 Shares issuable upon exercise of Lender Warrant to purchase common stock 12,
Slide 20: Investor Summary
Investor Summary 20 ~200 Healthcare Provider / Supplier Organizations ~400 Customer Organizations 1. Early - stage opportunity with a first mover advantage 2. $3B - $4B global biospecimen market growing at 10 - 15% per year 3. Unique two - sided marketplace disrupting the biospecimen procurement pro
Slide 21: Contact Us
CONNECT. INNOVATE. Sign up for free iSpecimen Marketplace account at www.ispecimen.com CONTACT US iSpecimen Inc. 450 Bedford Street Lexington, MA 02420 investors@ispecimen.com ispecimen.com
Slide 22: Appendix
Appendix 22
Slide 23: Strategic Evolution
Strategic Evolution PHASE 3 Expansion via the Online iSpecimen Marketplace Ƞ START UP Company Ideation and Self - Funding PHASE 1 Proof of Concept PHASE 2 Critical Mass of Suppliers and Early Customer Adoption 2010 – 2011 2012 – 2013 2014 – 2017 2018 – 2021 0 Customers 1 Supplier Agreement 0 Specime
Slide 24: iSpecimen Marketplace UI/UX: Tissue Search Example
iSpecimen Marketplace UI/UX Use Pulldowns to Enter Three High Level Search Criteria Tissue Search Example 24
Slide 25: iSpecimen Marketplace UI/UX: View Initial Results
to View Initial Results View Case Cards to See Specimens that Meet Criteria 25 iSpecimen Marketplace UI/UX
Slide 26: iSpecimen Marketplace UI/UX: Refine Search Results
Refine Search Results Using Sliders and Check Boxes Add Specimens to the Cart iSpecimen Marketplace UI/UX 26
Slide 27: iSpecimen Marketplace UI/UX: Cart and Request a Quote
View Cart and Add More Specimens Request a Quote iSpecimen Marketplace UI/UX 27 Track and Manage Requests
Slide 28: Sources Cited
28 Page Note Source Cited 7 1 iSpecimen estimates based on In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product, By Application, By Technology (Immunochemistry, Molecular Diagnostics) By End - use, By Region, And Segment Forecasts, 2021 – 2027. Grandview Research, January 2021